Free Trial

Arcus Biosciences (RCUS) Competitors

Arcus Biosciences logo
$8.70 +0.14 (+1.64%)
As of 05/19/2025 03:59 PM Eastern

RCUS vs. PTCT, SRPT, RNA, SWTX, RARE, AKRO, ACLX, ZLAB, VKTX, and CRNX

Should you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), Arcellx (ACLX), Zai Lab (ZLAB), Viking Therapeutics (VKTX), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.

Arcus Biosciences vs.

Arcus Biosciences (NYSE:RCUS) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Arcus Biosciences has higher earnings, but lower revenue than PTC Therapeutics. Arcus Biosciences is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcus Biosciences$141M6.59-$307M-$4.19-2.10
PTC Therapeutics$1.77B2.10-$626.60M$6.517.21

PTC Therapeutics received 377 more outperform votes than Arcus Biosciences when rated by MarketBeat users. However, 65.57% of users gave Arcus Biosciences an outperform vote while only 62.11% of users gave PTC Therapeutics an outperform vote.

CompanyUnderperformOutperform
Arcus BiosciencesOutperform Votes
200
65.57%
Underperform Votes
105
34.43%
PTC TherapeuticsOutperform Votes
577
62.11%
Underperform Votes
352
37.89%

In the previous week, PTC Therapeutics had 7 more articles in the media than Arcus Biosciences. MarketBeat recorded 14 mentions for PTC Therapeutics and 7 mentions for Arcus Biosciences. Arcus Biosciences' average media sentiment score of 1.48 beat PTC Therapeutics' score of 0.69 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arcus Biosciences
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PTC Therapeutics
10 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

92.9% of Arcus Biosciences shares are held by institutional investors. 12.3% of Arcus Biosciences shares are held by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PTC Therapeutics has a net margin of -50.32% compared to Arcus Biosciences' net margin of -102.66%. PTC Therapeutics' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcus Biosciences-102.66% -45.59% -22.38%
PTC Therapeutics -50.32%N/A -16.44%

Arcus Biosciences presently has a consensus price target of $25.67, indicating a potential upside of 192.33%. PTC Therapeutics has a consensus price target of $61.92, indicating a potential upside of 31.86%. Given Arcus Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Arcus Biosciences is more favorable than PTC Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcus Biosciences
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.91
PTC Therapeutics
1 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.67

Arcus Biosciences has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Summary

Arcus Biosciences beats PTC Therapeutics on 10 of the 18 factors compared between the two stocks.

Get Arcus Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCUS vs. The Competition

MetricArcus BiosciencesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$929.67M$6.51B$5.41B$19.72B
Dividend YieldN/A2.67%5.22%3.84%
P/E Ratio-2.799.1727.0435.27
Price / Sales6.59251.58393.5334.16
Price / CashN/A65.8538.2517.51
Price / Book1.426.516.804.77
Net Income-$307M$143.73M$3.23B$1.02B
7 Day Performance-0.40%2.64%2.54%0.77%
1 Month Performance11.35%9.36%10.78%10.35%
1 Year Performance-48.05%-4.13%15.57%5.21%

Arcus Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCUS
Arcus Biosciences
3.7195 of 5 stars
$8.70
+1.6%
$25.67
+195.0%
-48.5%$921.20M$141M-2.76500Positive News
PTCT
PTC Therapeutics
4.2452 of 5 stars
$46.01
+4.0%
$61.92
+34.6%
+41.9%$3.65B$1.77B-7.751,410Trending News
SRPT
Sarepta Therapeutics
4.784 of 5 stars
$36.37
+0.3%
$131.22
+260.8%
-71.1%$3.57B$2.23B29.10840Gap Up
High Trading Volume
RNA
Avidity Biosciences
1.9339 of 5 stars
$29.33
+5.2%
$66.38
+126.3%
+2.4%$3.53B$10.90M-10.18190Options Volume
SWTX
SpringWorks Therapeutics
2.3633 of 5 stars
$46.12
-0.3%
$52.57
+14.0%
+3.2%$3.46B$191.59M-13.25230Positive News
High Trading Volume
RARE
Ultragenyx Pharmaceutical
4.4429 of 5 stars
$36.09
+2.8%
$90.93
+152.0%
-13.6%$3.32B$590.69M-5.691,310Positive News
AKRO
Akero Therapeutics
3.898 of 5 stars
$41.53
+4.2%
$76.29
+83.7%
+91.5%$3.31BN/A-11.0730Insider Trade
High Trading Volume
ACLX
Arcellx
1.8289 of 5 stars
$59.50
+3.4%
$109.31
+83.7%
+9.1%$3.28B$76.81M-83.8080Positive News
ZLAB
Zai Lab
2.6421 of 5 stars
$29.40
+0.5%
$47.37
+61.1%
+70.1%$3.24B$418.33M-10.611,950Gap Up
VKTX
Viking Therapeutics
4.4801 of 5 stars
$28.30
+2.7%
$87.15
+208.0%
-59.0%$3.18BN/A-28.3020Positive News
Gap Down
CRNX
Crinetics Pharmaceuticals
3.704 of 5 stars
$33.32
+8.6%
$73.00
+119.1%
-39.8%$3.12B$1.04M-8.93210

Related Companies and Tools


This page (NYSE:RCUS) was last updated on 5/20/2025 by MarketBeat.com Staff
From Our Partners